Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons
详细信息 查看全文
- 作者：Lorraine Tafra MD (1)
- 刊名：Annals of Surgical Oncology
- 出版年：2007
- 出版时间：January 2007
- 年：2007
- 卷：14
- 期：1
- 页码：3-13
- 全文大小：581KB
- 参考文献：1. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15(2):61鈥? CrossRef
2. Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of 18F-FDG in the lactating breast. J Nucl Med 2001; 42:1238鈥?242
3. Nieweg OE, Kim EE, Wong EH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18 deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71:3920鈥?925 CrossRef
4. Aliaga A, Rousseau JA, Ouellette R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004; 31(6):761鈥?0 CrossRef
5. Schuster DM, Halkar RK. Molecular imaging in breast cancer. Radiol Clin North Am 2004; 42(5):885鈥?08, vi鈥搗ii CrossRef
6. Krak NC, van der Hoeven JJ, Hoekstra OS, et al. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 2003; 30(5):674鈥?1 CrossRef
7. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11(10):1115鈥?4 CrossRef
8. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35(2):84鈥?9 CrossRef
9. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43(4):500鈥?
10. Semple SI, Gilbert FJ, Redpath TW, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 2004; 14(11):2038鈥?5 CrossRef
11. Wolf G, Aigner RM, Schaffler G, et al. The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Breast Cancer Res Treat 2004; 88(3):205鈥? CrossRef
12. Byrne AM, Hill AD, Skehan SJ, et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg 2004; 91(11):1398鈥?09 CrossRef
13. Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11(9):846鈥?3 CrossRef
14. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22(2):277鈥?5 CrossRef
15. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005; 11(3):204鈥? CrossRef
16. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27(4):407鈥?0 CrossRef
17. Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2001; 2(3):229鈥?4
18. Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004; 15(9):1352鈥? CrossRef
19. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using F18-fluorodeoxy-d-glucose to predict the pathological response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676鈥?688
20. Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75(2):135鈥?6 CrossRef
21. van Oost FJ, van der Hoeven JJ, Hoekstra OS, et al. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer 2004; 40(10):1545鈥?3 CrossRef
22. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and 鈥渃onventional diagnostic procedures鈥?for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002; 23(9):857鈥?4 CrossRef
23. Goerres GW, Michel SC, Fehr MK, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13(7):1635鈥?4 CrossRef
24. Grahek D, Montravers F, Kerrou K, et al. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004; 31(2):179鈥?8 CrossRef
25. Walter C, Scheidhauer K, Scharl A, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003; 13(7):1651鈥? CrossRef
26. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31(7):932鈥? CrossRef
27. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004; 130(5):266鈥?2 CrossRef
28. Thompson CJ, Murthy K, Weinberg IN, Mako F. Feasibility study for positron emission mammography. Med Phys 1994; 21(4):529鈥?8 CrossRef
29. Bergman AM, Thompson CJ, Murthy K, et al. Technique to obtain positron emission mammography images in registration with X-ray mammograms. Med Phys 1998; 25(11):2119鈥?9 CrossRef
30. Doshi NK, Shao Y, Silverman RW, Cherry SR. Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 2000; 27(7):1535鈥?3 CrossRef
31. Thompson CJ, Murthy K, Aznar M, et al. Preliminary clinical evaluation of an instrument for 鈥減ositron emission mammography鈥?in the detection of breast cancer. Clin Positron Imaging 1998; 1(4):265 CrossRef
32. Weinberg I, Majewski S, Weisenberger A, et al. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med 1996; 23(7):804鈥? CrossRef
33. Qi J, Huesman RH. Scatter correction for positron emission mammography. Phys Med Biol 2002; 47(15):2759鈥?1 CrossRef
34. Weinberg IN, Beylin D, Zavarzin V, et al. Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 2005; 4(1):55鈥?0
35. Levine EA, Freimanis RI, Perrier ND, et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 2003; 10(1):86鈥?1 CrossRef
36. Rosen EL, Turkington TG, Soo MS, et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005; 234(2):527鈥?4 CrossRef
37. Tafra L, Cheng Z, Uddo J, et al. Pilot clinical trial of FDG positron emission mammography (PEM) in the surgical management of breast cancer. Ann Surg Oncol 2005; 190(4):628鈥?2
38. Raylman RR, Majewski S, Weisenberger AG, et al. Positron emission mammography-guided breast biopsy. J Nucl Med 2001; 42(6):960鈥?
39. Smith MF, Raylman RR, Majewski S, Weisenberger AG. Positron emission mammography with tomographic acquisition using dual planar detectors: initial evaluations. Phys Med Biol 2004; 49(11):2437鈥?2 CrossRef
40. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36(2):417鈥?8 CrossRef
41. Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004; 6(5):350鈥? CrossRef
42. Alauddin MM, Shahinian A, Gordon EM, Conti PS. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 2004; 3(2):76鈥?4 CrossRef
43. Fei X, Wang JQ, Miller KD, et al. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004; 31(8):1033鈥?1 CrossRef
44. Liu CS, Shen YY, Lin CC, et al. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002; 32(7):244鈥? CrossRef
45. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998; 58(20):4581鈥?
46. Mannie A, Cheng Z, Sawyer K, Tafra L, Whitworth P, Verbanac K. Use of circulating tumor cells and serum protein markers to monitor breast cancer patients at high risk for recurrent disease. Abstract Book: American Society of Breast Surgeons Annual Meeting, 16鈥?0 March 2005, Los Angeles, CA, USA
47. Higashi T, Saga T, Ishimori T, et al. What is the most appropriate scan timing for intraoperative detection of malignancy using 18F-FDG-sensitive gamma probe? Preliminary phantom and preoperative patient study. Ann Nucl Med 2004; 18(2):105鈥?4 CrossRef - 作者单位：Lorraine Tafra MD (1)
1. The Breast Center, Anne Arundel Medical Center, 2002 Medical Parkway, Suite 120, Annapolis, MD, 21401, USA
文摘